CONTACT-01:阿替利珠单抗联合卡博替尼对比多西他赛用于经检查点抑制剂和化疗后进展的转移性非小细胞肺癌的随机III期试验
CONTACT-01是一项多中心、开放标签、随机III期试验,比较阿替利珠单抗联合卡博替尼与多西他赛在经抗PD-L1/PD-1和含铂化疗后进展的转移性非小细胞肺癌患者中的疗效。主要终点总生存期(OS)在两组间无显著差异:联合组中位OS 10.7个月(95%CI 8.8-12.3)vs 多西他赛组10.5个月(95%CI 8.6-13.0),分层HR 0.88(95%CI 0.68-1.16;P=0.3668)。联合组中位无进展生存期(PFS)为4.6个月(95%CI 4.1-5.6),多西他赛组为4.0个月(95%CI 3.1-4.4),分层HR 0.74(95%CI 0.59-0.92)。安全性与此前已知的两药特征一致。
要点
- 联合组与多西他赛组中位OS分别为10.7个月和10.5个月,分层HR 0.88(95%CI 0.68-1.16;P=0.3668),无显著差异。
- 联合组中位PFS为4.6个月,多西他赛组为4.0个月,分层HR 0.74(95%CI 0.59-0.92)。
- 联合组严重不良事件发生71例(38.4%),多西他赛组58例(34.7%);3/4级治疗相关不良事件分别为73例(39.5%)和58例(34.7%)。
核心结论
- 在经抗PD-L1/PD-1免疫治疗和含铂化疗后进展的转移性非小细胞肺癌患者中,阿替利珠单抗联合卡博替尼对比多西他赛未改善总生存期。
- 安全性与此前已知的两药特征一致。
研究设计与样本
- 多中心、开放标签、随机III期试验(CONTACT-01,ClinicalTrials.gov标识符NCT04471428)。
- 患者按1:1随机分配至阿替利珠单抗1200 mg静脉注射每3周一次联合卡博替尼40 mg口服每日一次组(186例)或多西他赛75 mg/m²静脉注射每3周一次组(180例)。
- 主要终点为总生存期(OS)。
主要发现
- 联合组中位OS为10.7个月(95%CI 8.8-12.3),多西他赛组为10.5个月(95%CI 8.6-13.0),分层HR 0.88(95%CI 0.68-1.16;P=0.3668)。
- 联合组中位PFS为4.6个月(95%CI 4.1-5.6),多西他赛组为4.0个月(95%CI 3.1-4.4),分层HR 0.74(95%CI 0.59-0.92)。
- 联合组严重不良事件发生71例(38.4%),多西他赛组58例(34.7%)。
- 联合组3/4级治疗相关不良事件发生73例(39.5%),多西他赛组58例(34.7%)。
- 联合组5级不良事件发生14例(7.6%),多西他赛组10例(6.0%);其中治疗相关分别为4例(2.2%)和1例(0.6%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although checkpoint inhibitors have improved first-line treatment for non-small cell lung cancer (NSCLC), a therapeutic need remains for patients whose disease does not respond or who experience disease progression after anti-PD-L1/PD-1 immunotherapy. CONTACT-01 (ClinicalTrials.gov identifier: NCT04471428) evaluated atezolizumab plus cabozantinib versus docetaxel in patients with metastatic NSCLC who developed disease progression after concurrent or sequential treatment with anti-PD-L1/PD-1 and platinum-containing chemotherapy. METHODS: This multicenter, open-label, phase III trial randomly assigned patients 1:1 to atezolizumab 1,200 mg intravenously once every 3 weeks (q3w) plus cabozantinib 40 mg orally once daily or docetaxel 75 mg/m2 intravenously once every 3 weeks. The primary end point was overall survival (OS). RESULTS: One hundred eighty-six patients were assigned atezolizumab plus cabozantinib, and 180 docetaxel. Minimum OS follow-up was 10.9 months. Median OS was 10.7 months (95% CI, 8.8 to 12.3) with atezolizumab plus cabozantinib and 10.5 months (95% CI, 8.6 to 13.0) with docetaxel (stratified hazard ratio [HR], 0.88 [95% CI, 0.68 to 1.16]; P = .3668). Median progression-free survival was 4.6 months (95% CI, 4.1 to 5.6) and 4.0 months (95% CI, 3.1 to 4.4), respectively (stratified HR, 0.74 [95% CI, 0.59 to 0.92]). Serious adverse events (AEs) occurred in 71 (38.4%) patients receiving atezolizumab plus cabozantinib and 58 (34.7%) receiving docetaxel. Grade 3/4 treatment-related AEs occurred in 73 (39.5%) patients receiving atezolizumab plus cabozantinib and 58 (34.7%) receiving docetaxel. Grade 5 AEs occurred in 14 (7.6%) and 10 (6.0%) patients in the atezolizumab plus cabozantinib and docetaxel arms, respectively (treatment-related in four [2.2%] and one [0.6%], respectively). CONCLUSION: Atezolizumab plus cabozantinib after disease progression following anti-PD-L1/PD-1 immunotherapy and platinum-containing chemotherapy for metastatic NSCLC did not improve OS compared with docetaxel. Safety was consistent with known profiles of these agents.
引用
- Neal J, Pavlakis N, Kim SW, et al. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. J Clin Oncol. 2024. PMID: 38552197. doi:10.1200/JCO.23.02166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。